Close Menu

People in the News

Dec 12, 2019

Viracor Eurofins: Karina Eterovic

Viracor Eurofins has appointed Karina Eterovic as the director of research and development for oncology diagnostics for Eurofins' US clinical diagnostics group. Eterovic joined the firm from MD Anderson Cancer Center, where she was associate professor and director of the cancer genomics laboratory and drove the implementation of precision medicine. Further, at MD Anderson she established a genomics laboratory for NGS research projects, enabling the discovery and identification of new biomarkers for personalized cancer care. 

Dec 12, 2019

Digital Pathology Association: Michael Rivers

The Digital Pathology Association announced Michael Rivers has been named its new president, effective Jan. 1, 2020. Rivers is currently the vice president of Roche Digital Pathology and has been the head of the division since 2015, leading the digital pathology teams in California and Arizona. He joined Roche Tissue Diagnostics in 2006. Rivers will replace outgoing DPA President Marilyn Bui. 

Dec 09, 2019

Roche: Andreas Oeri, John Bell

Roche announced Andreas Oeri will retire from the company's board of directors in 2020, to be replaced by Jörg Duschmalé. Oeri was previously chairman of the company's corporate governance and sustainability committee. Also, the company said that John Bell will not stand for reelection to the board in 2020, and the board has proposed Patrick Frost, CEO of the Swiss Life Group, for his replacement. 

Additionally, Gottlieb Keller, Roche's general counsel, a member of the corporate executive committee, and the board's secretary, will retire in March 2020 after 35 years at the company. Claudia Böckstiegel, who is currently the head of legal of Roche's diagnostics division, will take over as general counsel. On April 1, 2020, she will also become a member of the Enlarged Corporate Executive committee. Annette Luther, the current general manager of Roche Diagnostics International, will be the new secretary to the board. 

Dec 06, 2019

Everlywell: Judith Rodin, Betsy Nabel, Martin Chavez, Others

Everlywell appointed Judith Rodin as an independent member of its board. The company also named seven new members to its scientific advisory board. Rodin has been a board member of Aetna, Citibroup, and Comcast NBCUniversal. She also was an advisor to President Clinton as a member of the President's Committee of Advisors on Science and Technology. In 1994, she became the first woman permanently appointed to lead an Ivy League university, the University of Pennsylvania, and she was president of the Rockefeller Foundation for more than a decade. 

The new members of Everlywell's scientific advisory board are Betsy Nabel, president of Brigham Health and professor of medicine at Harvard Medical School; Martin Chavez, chief of maternal fetal medicine at NYU Winthrop Hospital; Gregory Heath, former executive at Illumina and Roche Diagnostics; and Naglaa Rizk, assistant professor at Rutgers University and medical director of ambulatory services at Bergen New Bridge Medical Center.

Also named to the company's SAB were Robert Klees, research scientist at the Wadsworth Center of the New York State Department of Health; Mark DePristo, CEO and founder of BigHat Biosciences and founder of the Genomics team at Google Brain; and Marie McDonnell, chief of the diabetes section at Brigham and Women's Hospital, and lecturer at Harvard Medical School. 

Dec 06, 2019

Centogene: Philip Lambert, Peter Bauer

Philip Lambert has become CSO of Centogene, replacing Peter Bauer, who is now the firm's chief genomic officer. Lambert joins the company from Life Biosciences, where he was senior VP of discovery and labs as well as chief operating officer of two subsidiaries, Selphagy Therapeutics and Spotlight Biosciences. Prior to that, he was scientific partner and head of discovery at Charles River Laboratories. He also cofounded preclinical screening firm VivoPath. Lambert holds a PhD in neuropharmacology from Imperial College London and a BSc in pharmacology from the University of Liverpool.

Dec 06, 2019

Biovica: Henrik Winther

Biovica has appointed Henrik Winther senior vice president of business development. He started his position in November. Winther was previously SVP of precision diagnostics at Immunovia, and before that was global VP of business development at Dako, now part of Agilent Technologies, where he became GM of the companion diagnostic division. 


Dec 05, 2019

Celcuity: Richard Buller

Cell-based diagnostics firm Celcuity has appointed Richard Buller to its board of directors, effective Dec. 3. Buller was most recently head of oncology clinical development and vice president of translational oncology at Pfizer before retiring in 2016. Before that, he was vice president of translational medicine at Exelixis.

Dec 04, 2019

Accelerate Diagnostics: Lawrence Mehren, Jack Phillips

Lawrence Mehren will retire from his position as CEO of Accelerate Diagnostics, effective Feb. 1. Jack Phillips, the company's chief operating officer, has been unanimously appointed to the position of CEO by the firm's board of directors. Mehren will remain as an advisor to Accelerate through 2021.

Dec 02, 2019

NeoGenomics: Lawrence Weiss

NeoGenomics has appointed Lawrence Weiss as the company's chief medical officer, effective Nov. 25. He has been NeoGenomics' CSO since December 2018. Prior to that, he had been the firm's director of pathology services since March 2016. Before joining NeoGenomics, Weiss was a pathologist and later laboratory director at Clarient Diagnostic Services.

Nov 26, 2019

LabCorp: Jeffrey Davis

Laboratory Corporation of American has appointed Jeffrey Davis to its board, effective Dec. 1. He will also serve on the company's audit committee and quality and compliance committee. Davis is currently CFO of the Qurate Retail Group and former CFO of JC Penney. He previously was CFO at Darden Restaurants and Walmart.

Nov 25, 2019

Exagen: Thierry Dervieux

Exagen announced the departure of Thierry Dervieux, its chief scientific officer, effective Dec. 9. The resignation was not a result of disagreement with the company relating to its operations, policies, or practices, the company said in documents filed with the US Securities and Exchange Commission. According to Dervieux's LinkedIn profile, he has been Exagen's CSO and medical director since 2010. 

Nov 15, 2019

Path AI: Michael Montalto

Path AI has appointed Michael Montalto its chief science officer. He joins the company from Bristol-Myers Squibb where he was vice president and head of translational sciences, translational medicine. Before that, he was cofounder of and an executive at Omnyx, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Montalto was the molecular imaging and diagnostics advanced technology leader at GE before that. 

Nov 14, 2019

PredictImmune: James Clark

PredictImmune has appointed James Clark as its chief technology officer.

Clark was previously CEO of EnteroBiotix, a developer of microbiome modulating therapeutics.

Prior to his work at EnteroBiotix, he was vice president of clinical laboratory operations at Inivata, chief technology officer at Enterome, vice president of research and development at MDxHealth, and chief operating officer at Response Genetics.

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

Nov 13, 2019

Danaher: Jessica Mega, Pardis Sabeti

Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.

Sabeti has been an investigator at Howard Hughes Medical Institute since November 2015, and is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University. She also teaches in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Sabeti holds degrees from the Massachusetts Institute of Technology, University of Oxford, and Harvard Medical School. 

Nov 13, 2019

Abbott: Robert Ford, Miles White

Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board. 

Nov 12, 2019

Prescient Medicine Holdings: Tony Grover

Tony Grover has been named the chief commercial officer of Prescient Medicine Holdings where he will build and execute go-to-market strategies. Grover was vice president of business development at Banyan Biomarkers. Prior to that, he held various positions at PhotoThera. His immediate focus at Prescient will be the LifeKit Predict test, an in vitro diagnostic test for identifying patients at risk of opioid addiction. The test received breakthrough device designation in February 2018. Another test, LifeKit Prevent, for the detection of precancerous polyps and early-stage carcinomas, received breakthrough device designation in August 2019. 

Nov 11, 2019

LetsGetChecked: Troy Cox

LetsGetChecked appointed Troy Cox to its board. He has more than 30 years of expereience in healthcare, most recently as president and CEO of Foundation Medicine, now part of Roche. Prior to that, he was senior vice president and an officer at Genentech. He joined the board of Sophia Genetics in July.

Nov 07, 2019

Glympse Bio: Tracey Dawson

Glympse Bio, a firm developing non-invasive disease detection and monitoring technology, has named Tracey Dawson as chief commercial officer and head of strategy. Dawson joins Glympse from Biogen, where she was VP of global product development and commercialization for the multiple sclerosis franchise. Prior to that she was group vice president and head of the US genetic disease franchise for Shire. She has also worked for Genentech and Eli Lilly, and holds a PhD in physical organic chemistry from the University of Hull.

Nov 07, 2019

Epify: Leander Van Neste

Epify, a company developing epigenetic biomarkers for cancer diagnosis, has appointed Leander Van Neste as chief scientific officer. Van Neste joins Epify from miDiagnostics, where he served as vice president of scientific and clinical affairs. He has also served as vice president of clinical and scientific affairs for MDxHealth. Van Neste also simultaneously held academic appointments, including as a professor at Ghent University from 2015 to 2018, and an assistant professor at Universiteit Maastricht from 2013 to 2016. Prior to this he was a visiting research associate at Johns Hopkins School of Medicine.

Nov 06, 2019

LabCorp: Brian Caveney, Mark Schroeder, John Ratliff

Laboratory Corporation of America has named Brian Caveney executive vice president and president of Diagnostics, and Mark Schroeder executive vice president and president of Diagnostics laboratory operations and global supply chain. Also, John Ratliff, CEO of LabCorp's Covance business, is leaving the company to pursue another opportunity. The changes took effect immediately. 

Caveney joined LabCorp as CMO in 2017. Before that he was CMO of Blue Cross Blue Shield of North Carolina. Schroeder has been with LabCorp since 2007 and assumed the role of enterprise-wide chief supply chain officer in 2016. 

Nov 05, 2019

Congenica: Heiner Dreismann

Heiner Dreismann has been appointed as a non-executive director and senior independent director of UK genome analysis firm Congenica. Previously, he was president and CEO of Roche Molecular Systems. He was also head of global business development at Roche Diagnostics and a member of Roche's global diagnostics executive committee. Since leaving Roche, he has been on the board of biotechnology and healthcare companies in the US, Europe, and Israel.

Nov 05, 2019

Accelerate Diagnostics: Roland Diggelmann

Roland Diggelmann has been appointed to Accelerate Diagnostics' board of directors. Diggelmann is currently CEO of Smith+Nephew, a British medical equipment manufacturing company, having recently succeeded Namal Nawana, the former CEO of Alere. Diggelmann previously served as CEO of Roche Diagnostics, and also worked in the orthopedics sector at Sulzer Orthopedics and Zimmer Group. 

Nov 05, 2019

Section 32: Steven Kafka

Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.

Nov 05, 2019

Biodesix: Scott Hutton, David Brunel

Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.

Hutton is currently Biodesix's COO and has more than 20 years of experience in the medical device, medical technology, and diagnostics industries. Prior to joining Biodesix, he was senior vice president and general manager of vascular interventions at Spectranetics, and VP, GM of neurosurgery at Medtronic.